Dynavax Technologies Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DVAX research report →
About the company
Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U. S.
- CEO
- Ryan Spencer
- IPO
- 2004
- Employees
- 405
- HQ
- EmeryVille, CA, US
Price Chart
- Market Cap
- $1.82B
- P/E
- -47.71
- P/S
- 5.51
- P/B
- 3.40
- EV/EBITDA
- -75.99
- Div Yield
- 0.00%
- Gross Margin
- 83.17%
- Op Margin
- 3.16%
- Net Margin
- -13.13%
- ROE
- -8.05%
- ROIC
- 1.18%
- Revenue
- $277.25M · 19.36%
- Net Income
- $27.31M · 527.44%
- EPS
- $0.21 · 523.39%
- Op Income
- $-4,122,000
- FCF YoY
- -37.63%
- 52W High
- $15.73
- 52W Low
- $9.20
- 50D MA
- $13.69
- 200D MA
- $11.19
- Beta
- 0.93
- Avg Volume
- 3.16M
Get TickerSpark's AI analysis on DVAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 26 | Deep Track Biotechnology Master Fund, Ltd. | other | 15,726,349 |
| Feb 10, 26 | Spencer Ryan | other | 165,000 |
| Feb 10, 26 | Spencer Ryan | other | 136,000 |
| Feb 10, 26 | Spencer Ryan | sell | 280,000 |
| Feb 10, 26 | Spencer Ryan | sell | 136,000 |
| Feb 10, 26 | Spencer Ryan | sell | 231,000 |
| Feb 10, 26 | Spencer Ryan | sell | 90,667 |
| Feb 10, 26 | Spencer Ryan | other | 379,620 |
| Feb 10, 26 | Spencer Ryan | sell | 350,000 |
| Feb 10, 26 | Spencer Ryan | sell | 50,000 |
Our DVAX coverage
Recent articles, reports, and earnings notes.
No research on DVAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVAX report →Similar companies
Peers in the same neighborhood.